The Venture Codex

Participated · Seed · Sep 2024

Rey.id builds a holistic health ecosystem that merges telehealth primary care, claim adjudication, care management, and fitness features into a single platform intended to optimise user wellbeing and insurer claim performance. Moving beyond selling traditional health insurance policies, the startup provides a ‘Prevention to Protection Integrated’ membership model that bundles comprehensive health services in one subscription for both individuals and groups. Rey is also positioning itself as a technology provider to conventional insurers through a modernised third-party administration (TPA) offering that emphasises continuous preventive and curative engagement rather than purely transactional claim processing. Its platform incorporates innovations such as a generative-AI expert system and electronic medical records (EMR) to streamline health claims and underwriting, solutions that have already been adopted by several Indonesian insurance companies. The company’s strategy centres on making health insurance financially sustainable by reducing claim losses through active health management. Although specific revenue or user figures were not disclosed, management highlighted multiple 2024 milestones and growing industry uptake of its technology as proof points. Fresh capital will fuel further product development and rollout of new health memberships and TPA capabilities aimed at sustaining comprehensive health protection.

Led · Equity · Jun 2021

Prixa operates a B2B digital health platform that includes an AI digital health assistant, telemedicine consultations, pharmacy deliveries and on‑demand lab diagnostics. It partners with healthcare payers such as insurance providers, corporations and third‑party administrators rather than selling directly to consumers. Through its B2B customers Prixa currently serves about 10 million patients and works with four major insurers, with six additional insurers in its short‑term pipeline. The company positions itself as a digital primary care platform focused on cost control for payers by managing patients outside tertiary care and reducing outpatient and downstream inpatient costs. Usage of the platform increased during the COVID‑19 pandemic, and Prixa plans to use new funding to scale its platform and customer base. Prixa launched in 2019 and has raised a total of $4.5 million to date.

Participated · Series D · Sep 2020

Finch Therapeutics develops investigational oral microbiome drugs designed to restore healthy gut microbiome composition and function, including complete microbiome communities and rationally selected consortia. Its lead program, CP101, is designed to deliver the full diversity of a healthy gut microbiome and met its primary efficacy endpoint for prevention of recurrent C. difficile infection in a large, placebo-controlled trial. Finch also develops FIN-211 for children with autism spectrum disorder with serious GI symptoms and is evaluating CP101 for chronic hepatitis B. The company uses its Human-First Discovery® platform to translate clinical data into engineered microbiome compositions targeting disease-modifying mechanisms. Finch has a strategic partnership with Takeda to develop strain-based programs for inflammatory bowel disease, including FIN-524 (ulcerative colitis) and FIN-525 (Crohn’s disease). The company intends to use new financing to advance CP101 through final clinical development and regulatory submission, initiate Phase 1b studies for FIN-211 and CP101 in new indications, and further develop its platform and pipeline. Finch Therapeutics is a clinical-stage company developing microbial therapies using two proprietary platforms: donor-derived Full‑Spectrum Microbiota (FSM) and Rationally‑Selected Microbiota (RSM). Its lead product, CP101 (an oral FSM capsule), is being evaluated in the potentially pivotal PRISM3 trial for prevention of recurrent C. difficile infection. Finch is also advancing FSM programs in Autism Spectrum Disorder, supporting an actively enrolling Phase II investigator-initiated study (NCT03408886) and holding FDA Fast Track designation for its pediatric ASD program. The company is expanding its pipeline into additional indications, including a preclinical RSM program in inflammatory bowel disease in partnership with Takeda Pharmaceuticals. Finch recently received Breakthrough Therapy designation from the FDA for its CDI program. The company completed a $53 million Series C to fund these clinical and preclinical efforts and advance its platforms toward regulatory milestones. Finch Therapeutics Group develops novel microbial therapies using a human-first discovery approach and machine-learning informed by high-throughput molecular data. Its lead candidate, CP101, is an orally administered, encapsulated Full-Spectrum Microbiota product derived from healthy donors and is being evaluated in the Phase 2 PRISM 3 study for recurrent C. difficile infections. CP101 has been awarded FDA Fast Track designation. Finch says it will advance additional therapeutic candidates into the clinic through sponsored programs and collaborations with Takeda and academic partners. The company operates the largest stool donation program in the world, manufactures approximately 1,000 microbial treatments per month, and—through collaboration with OpenBiome—distributes products to a network of more than 1,000 providers. Finch also cites a comprehensive intellectual property estate, including 29 issued patents, and strengthened its position via a 2017 strategic merger with Crestovo. Finch Therapeutics develops microbiome-based therapies using fecal transplant–derived material and a sophisticated bioinformatics platform to analyze donor and patient microbiota. The company employs clinically annotated datasets and a feedback loop to identify microbiota changes associated with targeted clinical outcomes. Finch announced a collaboration with Takeda Pharmaceuticals in which Takeda will pay an upfront $10 million for exclusive worldwide rights to FIN-524 and any follow-on products for irritable bowel diseases. FIN-524 is described as an investigational therapy for ulcerative colitis, aligning with Takeda’s gastrointestinal therapeutic focus. CEO Mark Smith emphasized the firm’s approach of mining donor-specific efficacy signals, citing a randomized trial in which a single donor produced a disproportionately large therapeutic effect. Finch aims to translate complex, multi-strain microbiota ecosystems into validated human therapies by learning from donor–patient response patterns.

Participated · Equity · May 2018

Heal offers on-demand in-home and virtual primary care, telepsychology (California only), and digital monitoring, incorporating remote diagnostics such as iPhone-based EKGs and diabetic retinopathy tools. The company emphasizes continuity of care and persistent patient monitoring to make care more data-driven, timely and affordable. Heal has linked patients with more than 200,000 home visits since its 2015 launch. It has expanded treatment areas to include teletherapy for mental health and deploys hardware and digital hubs to gather remote diagnostics. Services are available in New York, New Jersey, Washington, California, Georgia, Virginia, Maryland and Washington, D.C., with planned geographic growth. Revenue or other financial operating metrics beyond visit volume were not disclosed in the article. Heal operates a technology-enabled doctor house-calls service that schedules on-demand or planned visits 8AM–8PM, 365 days a year. Since launching in March 2015, the company has delivered over 60,000 house calls and claims to have driven more than $41 million in healthcare cost savings versus traditional care alternatives. Heal says its proprietary technology lowers healthcare operating costs and bureaucracy by 65 percent and enables visits that last up to 28 minutes, compared with a national average of 13 minutes. The service is in-network with major PPO insurers and is offered as a health benefit by many large employers. Heal has expanded coverage to include Sacramento and the Inland Empire and is available to over 70 percent of California residents and most residents in Washington D.C. and Northern Virginia. The company also offers comprehensive disease management targeting the roughly 60 percent of Americans with one or more chronic illnesses. Heal plans to use new capital to pursue new markets, explore new business models, and advance its technology platform. Heal is a Los Angeles-based service that dispatches board-certified and licensed physicians for on-demand house calls and scheduled primary-care visits. Launched last year, the company already services the entire state of California and has cared for more than 10,000 patients. Patients can request an on-demand consultation within a two-hour window or schedule visits in advance; roughly 75% of repeat customers book ahead. Visits cost the price of a co-pay or a flat fee of $99, and doctors are available seven days a week from 8 a.m. to 8 p.m. Heal accepts insurance from Blue Shield of California, Anthem Blue Cross of California, Cigna Healthcare, Aetna and United Healthcare and will begin accepting Medicare payments by November. The company plans to use its new funding to develop its technology platform, increase marketing, and build out its roster of physicians as it considers expansion into markets with primary-care shortages. Heal is a California-based provider of on-demand primary healthcare services led by Dr. Renee Dua. The company offers doctors who are available in Los Angeles and San Francisco any time 8 a.m. to 8 p.m., seven days a week for services that include annual physicals, blood tests, specialist recommendations and prescription delivery. A new advanced booking option allows patients to book a doctor for the next day after hours. Doctors on Heal use medical technologies including an AliveCor ECG for near-instant heart health analysis, a CellScope otoscope to record HD-quality video inside a patient’s ear, and Electronic Medical Records to give patients easy access to their medical history. Heal secured $5M in funding and intends to use the funds to expand operations to 15 markets over the next 12 months.

Led · Equity · Sep 2017

Kata.ai operates a platform that lets brands and companies run chatbots in native Bahasa Indonesia. The service works on Facebook Messenger, Line, Telegram, Slack, BBM, Twitter and Skype, while WhatsApp integration is not yet available. The company began as a personal assistant service under parent YesBoss Group and pivoted to chatbots after CEO Irzan Raditya identified the need for local-language solutions. Telkomsel is a visible client, using Kata.ai to enable customer top-ups, package changes and information queries. Kata.ai recently raised $3 million and plans to use the funds to hire AI and big-data talent and to build an in-house sales team. The team graduated from Microsoft’s accelerator program in India and says it may launch in other Southeast Asian markets next year, though there is no immediate expansion plan. The company emphasizes serving Indonesia’s large messaging user base but faces a local shortage of experienced AI and chatbot talent.